Showing posts with label Defactinib. Show all posts
Showing posts with label Defactinib. Show all posts

Tuesday, April 21, 2026

News From the SGO Annual Meeting 2026

I was excited to be attending the marriage of my nephew in North Carolina the weekend of April 11th. At the same time, the SGO Annual Meeting was taking place in Puerto Rico. I have followed news from the SGO meeting for many years and been an active patient advocate member since 2020. I even attended a few annual meetings in person.  I always enjoyed learning about the latest research and making connections with gyn oncs, researchers and other advocate members. 

This year's meeting theme was "Advancing Science. Empowering Teams. Embracing Change". Since I did not attend the annual meeting in person I will share information from a number of different sources regarding ovarian cancer research presented that weekend.

MedPage 

Chemo Combo Wins in Ovarian Cancer, but Single-Agent Therapy Still in the Game-NRG-GY019
https://www.medpagetoday.com/meetingcoverage/sgo/120749  Low Grade Ovarian Cancer
 
"chemotherapy plus letrozole as standard of care for low-grade serous ovarian carcinoma (LGSOC), as letrozole monotherapy failed to meet non-inferiority requirements for progression-free survival (PFS). However, a subgroup analysis showed a 50% reduction in recurrence with single-agent letrozole in patients who had no gross residual disease after surgery. Analysis of that subgroup -- comprising almost two-thirds of the patients randomized to letrozole monotherapy -- yielded a hazard ratio (HR) within the non-inferiority range." 
 
Novel Regimen Boosts Survival for Recurrent Platinum-Resistant Ovarian Cancer
 https://www.medpagetoday.com/meetingcoverage/sgo/120748
 
"Adding the glucocorticoid receptor antagonist relacorilant (Lifyorli) to nab-paclitaxel improved median overall survival (OS) by 4 months versus nab-paclitaxel alone. The regimen received FDA approval in March on the basis of an improvement in progression-free survival (PFS)." 
 
X 
  

 

Article from The Gynecologic Oncology Journal  @gynoncjnls

Identifying ovarian cancer with AI analysis of abdominal CT scans
Conclusion:
"Deep Learning using segmented abdominal-pelvic CT scans, particularly convolutional neural networks-based architecture, demonstrate strong potential for distinguishing Epithelial Ovarian Cancer (EOC)   from benign pelvic masses. Further studies are needed to create accurate Deep Learning models for early EOC detection. "

SGO Meeting News https://www.sgomeetingnews.org/ 

Mirvetuximab soravtansine plus carboplatin in folate receptor alpha-expressing recurrent platinum-sensitive ovarian cancer - late breaking abstract 

"The study included 125 patients with measurable, recurrent FRa-expressing PSOC and one prior line of platinum-based chemotherapy. ...MIRV plus carboplatin in recurrent  platinum-resistant ovarian cancer (PSOC) with an FRa greater than or equal to 25% can be safely administered with minor dose modifications and proactive adverse event management. It also achieved favorable objective response rates and progression-free survival rates, showed comparable efficacy to pre-poly (ADP-ribose) polymerase (PARP) inhibitor era benchmarks, and established the safety and efficacy of continuing MIRV after carboplatin for the first time.  The study suggests it can also be safe and effective to combine with carboplatin in the treatment of PROC, and to continue administering MIRV as a maintenance therapy after treatment with carboplatin."

A Clearer Signal in Ovarian Cancer 
https://www.sgomeetingnews.org/home/article/22964575/a-clearer-signal-in-ovarian-cancer 
 
"Emily O'Brien, MD, reported on the clinical performance of a ctDNA whole genome assay in patients with Stage III and IV ovarian cancer undergoing neoadjuvant chemotherapy (NACT), interval debulking surgery (IDS), and adjuvant chemotherapy (ACT).  ...The study followed 15 patients with advanced-stage, high-grade serous ovarian cancer treated between 2022 and 2024. ...Patients with persistent ctDNA positivity were more likely to have platinum-resistant or refractory disease, while one patient with platinum-sensitive recurrence demonstrated transient ctDNA clearance before becoming positive again at recurrence, suggesting ctDNA may capture evolving tumor biology in real time." 
ctDNA is still investigational and more testing needs to be done but there is promise that the clearance of ctDNA could lead to more personalized treatment. 

 If you attended the meeting please share in the comment section which studies you found most impactful to patient treatment. Thanks.

 Dee

Every Day is a Blessing! 

 

Posted by at No comments:
Labels: , , , , , , , , ,

Monday, March 17, 2025

From a Distance: SGO Annual Meeting 2025 - Ovarian Cancer Highlights

I was unable to attend the SGO Annual meeting this year due to a family commitment but I did follow along on X(Twitter).

To kept on top of the action, I followed SGO Social Media Ambassadors Social Media Ambassadors on X- @RiosDoriaMD , @nicoleflemingmd, @meddles28, and @ShannonWestin and others.

Here are some of their ovarian cancer research posts I found most interesting :

Trop-2 is a cell surface protein expressed by cancer cells 
ADC Antibody Drug Conjugate 
Stomatitis is inflammation of the mucous membranes of the mouth . 
58 patients in the study
 
GOG 3066/DENALI 
Azenosertib an enzyme inhibitor that binds to called Wee1 and disrupt cell reproduction. 
Cyclin E1 is a protein is encoded by the CCNE1 gene.

 

 GOG 3044
Afuresertib inhibitor of the serine/threonine protein kinase Akt (protein kinase B) . No significant difference in progression free or overall survival.

 


EWOC-1 was a study of three different chemotherapy regimens . Use of carboplatin alone was associated with poorer survival.

 

 Mirv MIRASOL Study of ocular events.

RAINFOL-01 study (NCT05579366)  

Rinatabart sesutecan (Rina-S) a novel folate receptor alpha (FRα)–targeted antibody-drug conjugate (ADC). The treatment in  heavily pretreated patients with platinum-resistant ovarian cancer  showed activity regardless of folate receptor alpha (FRα) expression level.

 Low Grade Serous Ovarian Cancer 

Combo of Avutometinib  a Ras-Raf-MEK-ERK signaling inhibitor and Defactinib is small molecule inhibtor of focal adhesion kinase (FAK) for KRAS + recurrent low grade OC.

Please let me know if I missed anything you felt was important for patients/ survivors. 

 I was happy to see ways that patient advocates, researchers and clinicians were able to   #MultiplyYourImpact ! 

Thank you Dr Fader (@amandanfader)  for your leadership!  I look forward to your vision for the future,  Dr Karen Lu (@karenluMD) !

Dee

Every Day is a Blessing! 

Posted by at No comments:
Labels: , , , , , , , , , ,
Subscribe to: Posts (Atom)